Advances in pre- and posttransplant immunologic testing in kidney transplantation
- PMID: 15013292
- DOI: 10.1016/j.transproceed.2003.11.019
Advances in pre- and posttransplant immunologic testing in kidney transplantation
Abstract
Pre- and posttransplant risk estimation in kidney transplantation is important for the selection of appropriate treatment strategies. Recently, using new immunologic tests, we made observations within the framework of the Collaborative Transplant Study that may influence clinical practice. Complement-dependent lymphocytotoxic panel reactivity as a measure of anti-HLA sensitization, although criticized for its low sensitivity, is a useful indicator of an increased risk of rejection. Using the more sensitive complement-independent ELISA methodology, which utilizes solubilized HLA molecules instead of lymphocytes, we found that recipients with preformed complement-dependent anti-HLA antibodies showed a decreased graft survival only if their antibodies were directed against both HLA class I and class II, whereas isolated reactivity only against HLA class I or class II was of no clinical consequence. Pretransplant serum-soluble CD30 (sCD30) was found to be an independent and highly predictive factor of immunologic risk. The effects of sCD30 and anti-HLA antibodies were additive. Importantly, even patients without anti-HLA antibodies showed a strong HLA matching effect if their pretransplant serum contained high levels of sCD30. Although the role of anti-HLA antibody formation after transplantation remains uncertain, ELISA-detected sCD30 was shown to indicate impending graft rejection as early as on posttransplant days 3 to 5. Another very sensitive indicator of impending rejection is provided by posttransplant monitoring of the cytotoxic T-lymphocyte effector genes, perforin and granzyme B, in peripheral blood using real-time PCR.
Similar articles
-
Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.Clin Transpl. 2007:219-26. Clin Transpl. 2007. PMID: 18642453
-
Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.Hum Immunol. 2007 Aug;68(8):652-60. doi: 10.1016/j.humimm.2007.05.004. Epub 2007 Jun 11. Hum Immunol. 2007. PMID: 17678719
-
Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.Transpl Immunol. 2012 Mar;26(2-3):81-7. doi: 10.1016/j.trim.2011.12.002. Epub 2011 Dec 13. Transpl Immunol. 2012. PMID: 22182633
-
[Significance of histocompatibility tests].Rinsho Byori. 1990 Feb;38(2):151-6. Rinsho Byori. 1990. PMID: 2139476 Review. Japanese.
-
Sensitization after kidney transplantation.Clin J Am Soc Nephrol. 2006 May;1(3):433-40. doi: 10.2215/CJN.01751105. Epub 2006 Jan 25. Clin J Am Soc Nephrol. 2006. PMID: 17699242 Review.
Cited by
-
Characterization of acute renal allograft rejection by proteomic analysis of renal tissue in rat.Mol Biol Rep. 2012 Feb;39(2):1315-22. doi: 10.1007/s11033-011-0864-5. Epub 2011 May 22. Mol Biol Rep. 2012. PMID: 21604175
-
Cytotoxic antibodies--valuable prognostic factor for long term kidney allograft survival.J Med Life. 2010 Oct-Dec;3(4):390-5. J Med Life. 2010. PMID: 21254736 Free PMC article.
-
Deciphering CD30 ligand biology and its role in humoral immunity.Immunology. 2006 Jun;118(2):143-52. doi: 10.1111/j.1365-2567.2006.02354.x. Immunology. 2006. PMID: 16771849 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials